HC Wainwright Analysts Increase Earnings Estimates for ZNTL

Key Points

• HC Wainwright raised its FY2026 EPS estimate to a loss of $1.85 per share from a previously projected loss of $2.39, while maintaining its Buy rating and $10 price target.
• Zentalis reported a quarterly loss of $0.34 per share, beating analysts’ consensus estimate of a $0.54 loss by $0.20.
• Analyst views are mixed but lean positive: MarketBeat reports a Moderate Buy consensus rating and an average price target of $8.29.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Zentalis Pharmaceuticals in a report released on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.85) for the year, up from their previous forecast of ($2.39). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.15) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals' Q4 2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.90) EPS, FY2028 earnings at ($1.64) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($0.42) EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Friday, October 2nd. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a "buy" rating and a $11.00 price target on the stock. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 30th. They set an "equal weight" rating and a $5.00 price target on the stock. Finally, Mizuho began coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an "outperform" rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Zentalis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $8.29.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $1.89 on Thursday. Zentalis Pharmaceuticals has a 1-year low of $1.28 and a 1-year high of $6.95. The company has a market cap of $135.46 million, a price-to-earnings ratio of -0.98 and a beta of 1.91. The stock has a 50 day simple moving average of $2.62 and a 200-day simple moving average of $3.39.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.20.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Group Walters purchased 4,335,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the acquisition, the insider directly owned 17,844,973 shares of the company's stock, valued at $62,457,405.50. This trade represents a 32.09% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ZNTL. CTC Alternative Strategies Ltd. acquired a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter valued at approximately $29,000. Spark Investment Management LLC acquired a new position in Zentalis Pharmaceuticals during the second quarter worth $61,000. The Manufacturers Life Insurance Company acquired a new position in Zentalis Pharmaceuticals during the second quarter worth $69,000. State of Wyoming purchased a new position in Zentalis Pharmaceuticals in the second quarter worth $91,000. Finally, Sei Investments Co. raised its position in Zentalis Pharmaceuticals by 14.6% in the first quarter. Sei Investments Co. now owns 191,551 shares of the company's stock worth $448,000 after acquiring an additional 24,451 shares in the last quarter.

Top Zentalis Pharmaceuticals Stories

Investors following ZNTL have been watching these stories:

• Positive Sentiment: Wedbush upgraded ZNTL from “Neutral” to “Outperform” and raised its price target to $6 from $5, signaling a more bullish view. Article: Zentalis Pharmaceuticals Stock Rating Upgraded by Wedbush
• Positive Sentiment: HC Wainwright raised its EPS estimates for 2026–2028, projecting smaller losses, including FY2027 EPS of ($1.90) versus its prior estimate of ($2.76), and maintained its “Buy” rating and $10 target. These improved forecasts are the main positive earnings signal, though the company is still expected to report losses. Zentalis Pharmaceuticals analyst estimates
• Negative Sentiment: HC Wainwright lowered its FY2029 and FY2030 EPS forecasts, to ($1.10) from ($1.00) and to ($0.42) from ($0.18), respectively, tempering the improved nearer-term outlook. Zentalis Pharmaceuticals analyst estimates

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. NASDAQ: ZNTL is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company's research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments. Zentalis' lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.